Nucleic acid simultaneously inhibiting expression of AR gene and mTOR gene
AssigneeCurigin Co., Ltd.
InventorsJin-Woo Choi, Jung-Ki Yoo
Life of this patent
Estimating the term…
Abstract
The present invention relates to nucleic acid molecules that simultaneously inhibit the expression of AR gene and mTOR gene, wherein the double-stranded siRNA and shRNA of the present invention were designed to simultaneously inhibit the expression of the AR gene and the mTOR gene which are associated with cancer. The double-stranded siRNA and shRNA of the present invention promote cancer cell death and synergistically enhance cancer cell death in combination with an anticancer agent, so that various types of cancer may be effectively prevented and treated.
Claims10
A double-stranded siRNA molecule in which SEQ ID NO:
- 1 partially complementarily binds to SEQ ID NO:
- 2, SEQ ID NO:
- 3 partially complementarily binds to SEQ ID NO:
- 4, SEQ ID NO:
- 5 partially complementarily binds to SEQ ID NO:
- 6, SEQ ID NO:
- 7 partially complementarily binds to SEQ ID NO:
- 8, SEQ ID NO:
- 9 partially complementarily binds to SEQ ID NO:
- 10, SEQ ID NO:
- 11 partially complementarily binds to SEQ ID NO:
- 12, SEQ ID NO:
- 13 partially complementarily binds to SEQ ID NO:
- 14, SEQ ID NO:
- 15 partially complementarily binds to SEQ ID NO:
- 16, SEQ ID NO:
- 17 partially complementarily binds to SEQ ID NO:
- 18, SEQ ID NO:
- 19 partially complementarily binds to SEQ ID NO:
- 20, SEQ ID NO:
- 21 partially complementarily binds to SEQ ID NO:
- 22, SEQ ID NO:
- 23 partially complementarily binds to SEQ ID NO:
- 24, or SEQ ID NO:
- 25 partially complementarily binds to SEQ ID NO:
- 26, or a double-stranded siRNA molecule having at least 80% sequence identity with respect to each strand of the above double-stranded siRNA molecule.
A nucleic acid molecule which is a shRNA molecule in which SEQ ID NO:
- 1 partially complementarily binds to SEQ ID NO:
- 2, SEQ ID NO:
- 3 partially complementarily binds to SEQ ID NO:
- 4, SEQ ID NO:
- 5 partially complementarily binds to SEQ ID NO:
- 6, SEQ ID NO:
- 7 partially complementarily binds to SEQ ID NO:
- 8, SEQ ID NO:
- 9 partially complementarily binds to SEQ ID NO:
- 10, SEQ ID NO:
- 11 partially complementarily binds to SEQ ID NO:
- 12, SEQ ID NO:
- 13 partially complementarily binds to SEQ ID NO:
- 14, SEQ ID NO:
- 15 partially complementarily binds to SEQ ID NO:
- 16, SEQ ID NO:
- 17 partially complementarily binds to SEQ ID NO:
- 18, SEQ ID NO:
- 19 partially complementarily binds to SEQ ID NO:
- 20, SEQ ID NO:
- 21 partially complementarily binds to SEQ ID NO:
- 22, SEQ ID NO:
- 23 partially complementarily binds to SEQ ID NO:
- 24, or SEQ ID NO:
- 25 partially complementarily binds to SEQ ID NO:
- 26, to form a hairpin structure, a shRNA molecule having at least 80% sequence identity with respect to each SEQ ID NO of the above shRNA molecule, or a DNA molecule encoding the shRNA molecule.
A method for treating cancer, the method comprising administering a pharmaceutically effective amount of a nucleic acid molecule to a subject in need thereof, wherein the nucleic acid molecule comprises:
- i) a double-stranded siRNA or a shRNA molecule in which SEQ ID NO:
- 1 partially complementarily binds to SEQ ID NO:
- 2, or SEQ ID NO:
- 15 partially complementarily binds to SEQ ID NO:
- 16,
- ii) a double-stranded siRNA or shRNA molecule having at least 80% sequence identity to each of SEQ ID NOS 1 and 2, or to each of SEQ ID NOS:
- 15 and 16, or
- iii) a DNA molecule that can express at least one of the foregoing shRNA molecules.
Dependencies are inferred from the claim text.